On February 26, 2026, the FDA granted expanded approval for Boehringer Ingelheim’s Hernexeos (zongertinib) as a first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring HER2-activating mutations. This landmark decision was issued through the FDA’s new Commissioner’s National Priority Voucher (CNPV) program, marking only the second time a drug has been approved under this accelerated pilot scheme designed to slash review times for critical therapies.
The approval, rendered just 44 days post-filing, was supported by clinical data from the Beamion Lung-1 study. In treatment-naive patients, Hernexeos delivered a robust objective response rate of 76%, with 64% of participants maintaining a response duration of at least six months. As the only once-daily oral therapy cleared for this specific patient population, it offers a simplified and powerful alternative to existing regimens.
This expansion is particularly significant for younger patients and non-smoking women, who represent a notable portion of the HER2-mutated lung cancer demographic and are often diagnosed at advanced stages. By securing a first-line indication ahead of schedule, Boehringer not only gains a competitive edge over rivals like Bayer but also provides a vital option for a community in desperate need of early, targeted intervention.